Trial Profile

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Nov 2025 According to a Rigel Pharmaceuticals media release, enrollment in the dose escalation phase is completed and first patient in the dose expansion has been enrolled.
03 Nov 2025 According to a Rigel Pharmaceuticals media release, updated results from our Phase 1b study in patients have been accepted for oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition on Sunday, December 7, 2025.
08 Oct 2025 According to a Rigel Pharmaceuticals media release, the company announced that first patient has been enrolled in the dose expansion phase of this trial.,and the company expects to share updated data from the study later this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com